Titlebook: Nanotherapy for Brain Tumor Drug Delivery; Vivek Agrahari,Anthony Kim,Vibhuti Agrahari Book 2021 Springer Science+Business Media, LLC, par

Macronutrients

Methods to Separate, Characterize, and Encapsulate Drug Molecules into Exosomes for Targeted Deliven, rhodamine) or large protein-based molecules (catalase) or nucleic acid-based drugs such as small interfering RNA (siRNA). In this chapter, we will focus on describing exosome isolation, characterization, and drug loading methods that are suitable for studying and treating glioblastoma.

jettison

Collar

Strategies to Modulate the Blood-Brain Barrier for Directed Brain Tumor Targeting,les is to get newly discovered therapeutic agents across the blood-brain barrier (BBB) to penetrate the brain parenchyma. In this context, this book chapter provides an overview of three different strategies of delivering antitumor agents intended to circumvent the BBB and highlight the strengths and weakness of each approach.

大看臺

Establishing Orthotopic Xenograft Glioblastoma Models for Use in Preclinical Development,e frontline of neuro-oncology as an experimental system to identify novel therapeutic targets and to determine the efficacy of different therapeutic agents and/or nanosystems. The present chapter describes a protocol for establishing brain tumor xenografts in mice following a single injection of glioblastoma cells.

內(nèi)部

Neuromethodshttp://image.papertrans.cn/n/image/661150.jpg

floaters

https://doi.org/10.1007/978-1-0716-1052-7brain cancer; malignant gliomas; Nano-biotechnology; stem cell; molecular imaging

大包裹

溫和女孩

兵團

Vivek Agrahari,Anthony Kim,Vibhuti AgrahariIncludes cutting-edge methods and protocols.Provides step-by-step detail essential for reproducible results.Contains key notes and implementation advice from the experts

松軟無力

Glioblastoma: State of the Art of Treatments and Applications of Polymeric and Lipidic Nanomedicinecovered in late stages and is normally deadly, having a life expectancy of 12–15?months and a mere 3% of the affected patients living 3?years or more independent of race, sex, and age. Sadly, current treatments (i.e., chemotherapy, radiation, surgery) are extremely aggressive and extend the patient’